Trade Keros Therapeutics, Inc. - KROS CFD

Add to favourite

58.21

1.6%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.19

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Keros Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	58.9
Open*	57.24
1-Year Change*	37.3%
Day's Range*	55.95 - 58.96
52 wk Range	27.02-59.96
Average Volume (10 days)	696.37K
Average Volume (3 months)	8.18M
Market Cap	1.72B
P/E Ratio	-100.00K
Shares Outstanding	33.18M
Revenue	8,000.00
EPS	-4.94
Dividend (Yield %)	N/A
Beta	1.20
Next Earnings Date	Mar 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	58.90	1.70	2.97%	57.20	60.96	57.07
Apr 17, 2024	59.21	2.87	5.09%	56.34	59.35	56.28
Apr 16, 2024	57.91	1.02	1.79%	56.89	58.67	55.94
Apr 15, 2024	57.55	-1.09	-1.86%	58.64	59.56	57.17
Apr 12, 2024	58.38	-1.56	-2.60%	59.94	62.17	58.06
Apr 11, 2024	61.85	0.90	1.48%	60.95	62.47	60.95
Apr 10, 2024	60.71	0.20	0.33%	60.51	62.97	59.96
Apr 9, 2024	63.75	1.25	2.00%	62.50	64.63	61.65
Apr 8, 2024	63.13	0.57	0.91%	62.56	63.60	60.79
Apr 5, 2024	62.60	2.00	3.30%	60.60	63.50	60.59
Apr 4, 2024	61.58	-3.03	-4.69%	64.61	65.41	61.35
Apr 3, 2024	63.86	1.06	1.69%	62.80	65.26	61.89
Apr 2, 2024	63.90	0.93	1.48%	62.97	64.86	62.97
Apr 1, 2024	66.82	0.84	1.27%	65.98	67.07	64.64
Mar 28, 2024	66.02	1.38	2.13%	64.64	66.78	63.01
Mar 27, 2024	64.56	5.52	9.35%	59.04	65.63	59.00
Mar 26, 2024	65.81	-1.18	-1.76%	66.99	67.33	65.04
Mar 25, 2024	66.12	2.08	3.25%	64.04	67.29	64.04
Mar 22, 2024	65.75	-3.06	-4.45%	68.81	68.87	65.17
Mar 21, 2024	68.86	2.03	3.04%	66.83	69.79	66.76

Keros Therapeutics, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Keros Therapeutics Inc Earnings Release Q1 2024 Keros Therapeutics Inc Earnings Release Forecast - Previous -
Wednesday, June 5, 2024
Time (UTC) 13:00	Country US	Event Keros Therapeutics Inc Annual Shareholders Meeting Keros Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Monday, August 5, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Keros Therapeutics Inc Earnings Release Q2 2024 Keros Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	20.1	0	10	10
Revenue	0	20.1	0	10	10
Total Operating Expense	114.79	76.473	46.657	20.563	11.691
Selling/General/Admin. Expenses, Total	27.525	21.33	12.797	3.184	1.58
Research & Development	87.265	55.143	33.86	17.379	10.111
Operating Income	-114.79	-56.373	-46.657	-10.563	-1.691
Interest Income (Expense), Net Non-Operating	-0.001	-0.004	-0.006	-0.008	0.006
Other, Net	10.112	-0.356	1.13	-1.765	0.607
Net Income Before Taxes	-104.679	-56.733	-45.533	-12.336	-1.078
Net Income After Taxes	-104.679	-58.744	-45.533	-12.336	-1.335
Net Income Before Extra. Items	-104.679	-58.744	-45.533	-12.336	-1.335
Net Income	-104.679	-58.744	-45.361	-12.336	-1.335
Income Available to Common Excl. Extra. Items	-104.679	-58.744	-45.533	-12.336	-1.335
Income Available to Common Incl. Extra. Items	-104.679	-58.744	-45.361	-12.336	-1.335
Diluted Net Income	-104.679	-58.744	-45.361	-12.336	-1.335
Diluted Weighted Average Shares	25.241	23.3339	15.5064	19.1894	19.1894
Diluted EPS Excluding Extraordinary Items	-4.14718	-2.51754	-2.9364	-0.64286	-0.06957
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-4.14718	-2.51754	-2.9364	-0.64286	-0.06957
Total Extraordinary Items			0.172
Total Adjustments to Net Income			0

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	41.337	38.869	31.96	27.976	30.728
Selling/General/Admin. Expenses, Total	8.803	7.778	7.093	6.937	7.447
Research & Development	32.534	31.091	24.867	21.039	23.281
Operating Income	-41.337	-38.869	-31.96	-27.976	-30.728
Interest Income (Expense), Net Non-Operating	0		0	0	0
Other, Net	3.832	3.065	2.242	4.467	3.462
Net Income Before Taxes	-37.505	-35.804	-29.718	-23.509	-27.266
Net Income After Taxes	-37.505	-35.804	-29.718	-23.509	-27.266
Net Income Before Extra. Items	-37.505	-35.804	-29.718	-23.509	-27.266
Net Income	-37.505	-35.804	-29.718	-23.509	-27.266
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items	-37.505	-35.804	-29.718	-23.509	-27.266
Income Available to Common Incl. Extra. Items	-37.505	-35.804	-29.718	-23.509	-27.266
Diluted Net Income	-37.505	-35.804	-29.718	-23.509	-27.266
Diluted Weighted Average Shares	29.6025	28.3694	27.3496	25.5497	24.054
Diluted EPS Excluding Extraordinary Items	-1.26696	-1.26206	-1.0866	-0.92013	-1.13353
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-1.26696	-1.26206	-1.0866	-0.92013	-1.13353
Revenue			0	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	285.767	251.44	267.726	8.927	25.531
Cash and Short Term Investments	279.048	230.042	265.876	7.02	23.259
Cash & Equivalents	279.048	230.042	265.876	7.02	23.259
Total Receivables, Net	0	18.197	0.216	0.922	0
Accounts Receivable - Trade, Net	0	18	0	0.922	0
Prepaid Expenses	5.698	2.861	1.474	0.155	2.188
Other Current Assets, Total	1.021	0.34	0.16	0.83	0.084
Total Assets	306.781	255.251	269.443	10.955	27.412
Property/Plant/Equipment, Total - Net	17.569	2.402	1.602	1.913	1.38
Property/Plant/Equipment, Total - Gross	18.732	3.248	2.323	2.366	1.626
Accumulated Depreciation, Total	-1.163	-0.846	-0.721	-0.453	-0.246
Note Receivable - Long Term				0	0.37
Other Long Term Assets, Total	3.445	1.409	0.115	0.115	0.131
Total Current Liabilities	16.547	11.846	7.184	4.486	11.469
Accounts Payable	3.339	3.645	2.149	2.088	0.501
Accrued Expenses	12.508	7.997	4.817	2.291	0.922
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.7	0.204	0.218	0.107	10.046
Total Liabilities	29.358	12.077	7.722	10.46	14.654
Total Long Term Debt	0	0	0	4.956	2.392
Long Term Debt			0	4.956	2.392
Other Liabilities, Total	12.811	0.231	0.538	1.018	0.793
Total Equity	277.423	243.174	261.721	0.495	12.758
Redeemable Preferred Stock			0		19.941
Common Stock	0.002	0.002	0.002	0.001	0.001
Additional Paid-In Capital	505.855	366.927	326.73	0.203	0.13
Retained Earnings (Accumulated Deficit)	-228.434	-123.755	-65.011	-19.65	-7.314
Total Liabilities & Shareholders’ Equity	306.781	255.251	269.443	10.955	27.412
Total Common Shares Outstanding	27.5434	23.9748	23.1929	19.1894	19.1894
Preferred Stock - Non Redeemable, Net				19.941

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	304.435	334.308	362.222	285.767	245.875
Cash and Short Term Investments	287.893	322.026	351.429	279.048	239.426
Cash & Equivalents	287.893	322.026	351.429	279.048	239.426
Total Receivables, Net				0	0.146
Prepaid Expenses	15.325	10.942	9.133	5.698	5.558
Other Current Assets, Total	1.217	1.34	1.66	1.021	0.745
Total Assets	326.247	356.306	384.436	306.781	252.55
Property/Plant/Equipment, Total - Net	19.026	19.097	19.297	17.569	2.127
Other Long Term Assets, Total	2.786	2.901	2.917	3.445	4.548
Total Current Liabilities	16.701	16.095	15.458	16.547	11.525
Accounts Payable	3.867	4.146	4.682	3.339	2.655
Accrued Expenses	12.431	11.539	10.515	12.508	8.583
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.403	0.41	0.261	0.7	0.287
Total Liabilities	30.405	30.046	29.452	29.358	11.525
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	13.704	13.951	13.994	12.811	0
Total Equity	295.842	326.26	354.984	277.423	241.025
Common Stock	0.003	0.003	0.003	0.002	0.002
Additional Paid-In Capital	637.022	628	619.219	505.855	439.739
Retained Earnings (Accumulated Deficit)	-341.183	-301.743	-264.238	-228.434	-198.716
Total Liabilities & Shareholders’ Equity	326.247	356.306	384.436	306.781	252.55
Total Common Shares Outstanding	29.6791	29.661	29.5487	27.5434	26.0772
Accounts Receivable - Trade, Net				0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-104.679	-58.744	-45.361	-12.336	-1.335
Cash From Operating Activities	-70.062	-62.148	-36.894	-15.998	7.042
Cash From Operating Activities	0.674	0.378	0.278	0.208	0.153
Non-Cash Items	19.635	12.288	5.914	2.854	0.275
Cash Taxes Paid			0	0.256	0
Changes in Working Capital	14.308	-16.07	2.275	-6.724	7.949
Cash From Investing Activities	-1.241	-1.024	-0.294	-0.271	-0.217
Capital Expenditures	-1.241	-1.024	-0.294	-0.271	-0.217
Cash From Financing Activities	120.309	28.55	296.044	0.014	11.463
Financing Cash Flow Items	-0.087	0	-3.196	0	-0.045
Issuance (Retirement) of Stock, Net	120.396	28.55	299.24	0.014	11.508
Net Change in Cash	49.006	-34.622	258.856	-16.255	18.288

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-35.804	-104.679	-74.961	-51.452	-24.186
Cash From Operating Activities	-34.235	-70.062	-48.619	-24.017	-1.427
Cash From Operating Activities	0.167	0.674	0.547	0.421	0.113
Non-Cash Items	6.213	19.635	14.567	9.591	4.591
Changes in Working Capital	-4.811	14.308	11.228	17.423	18.055
Cash From Investing Activities	-1.062	-1.241	-0.89	-0.714	-0.147
Capital Expenditures	-1.062	-1.241	-0.89	-0.714	-0.147
Cash From Financing Activities	107.678	120.309	58.893	10.31	0.118
Financing Cash Flow Items		-0.087
Issuance (Retirement) of Stock, Net	107.678	120.396	58.893	10.31	0.118
Net Change in Cash	72.381	49.006	9.384	-14.421	-1.456

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Keros Therapeutics, Inc. Company profile

About Keros Therapeutics Inc

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressive (FOP), a musculoskeletal disorder. Its third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension (PAH).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Keros Therapeutics Inc revenues increased from $0K to $20.1M. Net loss before extraordinary items increased 29% to $58.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 56% to $50.9M (expense).

Industry:

Bio Therapeutic Drugs

1050 Waltham Street, Suite 302
LEXINGTON
MASSACHUSETTS 02421
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024